Study name |
COPLA Study: treatment of severe forms of coronavirus infection with convalescent plasma |
Methods |
|
Participants |
-
Inclusion criteria
SARS‐CoV2 infection with serious evolution and in ICU
With or without ventilatory assistance
Treated or not with hydroxychloroquine 200 mg every 12 h
Either sex
> 18 years
Signed informed consent
-
Exclusion criteria
Treated with the following medications: azithromycin, ritonavir/lopinavir, remdesivir, interferons, ruxolinitib, tocilizumab
Severe kidney failure who require replacement therapy
|
Interventions |
CP therapy or hyperimmune globulin therapy: CP therapy
-
Details of CP:
Treatment details, including time of plasma therapy (e.g. early stage of disease): NR
For studies including a control group: comparator (type): none
Concomitant therapy: with or without ventilation, hydroxychloroquine
Treatment cross‐overs: none
|
Outcomes |
|
Starting date |
13 April 2020 |
Contact information |
Juan Carlos Olivares‐Gazca, MD, MPH; 2222438100; jolivares@hsctmexico.com José Manuel Priesca‐Marin, MD; 2222438100; mpriesca@hsctmexico.com
|
Notes |
Recruitment status: recruiting
Prospective completion date: August 2020
Sponsor/funding: Centro de Hematología y Medicina Interna
|